Butterfly Network's chip licensing drove 71% U.S. growth; CEO says it will dwarf the probe business
The chip story is already revenue: third-quarter US growth of 71 percent came primarily from Embedded, Butterfly's chip-licensing line, including the Midjourney co-development. That counterparty has no outside investors and three studios suing it, and insider sale filings landed the same fortnight.
Richard Tangfour-minute read
Butterfly Network's+1.23% — Butterfly Network, up 1.23 percent today chief executive, Joe DeVivo, told UBS's medtech team this month that revenue from licensing the company's ultrasound semiconductor should "begin to dwarf" the handheld-probe business within a couple of years, citing more than 12 licensing partners and a fourth-generation chip due next quarter 1. The filings from the same fortnight support the direction and set the limit: the chip money is real, and its most visible consumer endpoint belongs to Midjourney, the AI image-generation company, which has no outside investors and three studios suing it 23.
The chip money is real; the fourth-quarter guide holds it flat
Revenue stepped up to $32.6 million in the second quarter and held there in the third 9. Butterfly attributes the 71 percent jump in US revenue primarily to Embedded, its business licensing the Ultrasound-on-Chip to other companies, including the co-development with Midjourney 2. Gross margin, at 73 percent, was the highest in the company's history 2. The quarter still lost $12.8 million 2. Cash stands at $122.3 million 2.
Operating cash has run negative in seven of eight quarters, and cash is down to $122 million
- Operating cash flow
- Cash at quarter end
Data
| Operating cash flow | Cash at quarter end | |
|---|---|---|
| Q4 '24 | -$3.12M | $88.78M |
| Q1 '25 | -$11.68M | $155.21M |
| Q2 '25 | -$7.17M | $148.14M |
| Q3 '25 | -$2.89M | $144.23M |
| Q4 '25 | $9.03M | $150.49M |
| Q1 '26 | -$13.89M | $137.95M |
| Q2 '26 | -$16.27M | $124.66M |
| Q3 '26 | -$2.27M | $122.3M |
Butterfly's own fourth-quarter guide, $31 million to $34 million, holds revenue on that plateau, and the last step of this size, in late 2025, fell back the following quarter 29. We showed how milestone money shaped this quarter when it landed on October 29; what is new since is the quote itself, from UBS's November 10, 2026, healthcare conference, and the filings that followed it 15.
A partner payment lifts one quarter; only shipped product brings the next one.
Butterfly's revenue stepped up to a plateau, and its own Q4 guide holds it flat
A step up to $32.6 million, held flat by the company's own guide
- Revenue
- Estimate
Data
| Revenue | |
|---|---|
| Q4 '24 | $22.35M |
| Q1 '25 | $21.23M |
| Q2 '25 | $23.38M |
| Q3 '25 | $21.49M |
| Q4 '25 | $31.51M |
| Q1 '26 | $26.53M |
| Q2 '26 | $32.61M |
| Q3 '26 | $32.6M |
| Q4 '26 guide (estimate) | $32.5M ($31–34M) |
The consumer end of the chip story is a defendant
The Embedded product a consumer can touch is Midjourney's full-body scanner, built around 40 Butterfly ultrasound chips 4. At launch it will map body composition only, a choice that avoids the approvals diagnostic imaging requires, with availability planned by the end of 2027 4. It begins with about ten scanners in a San Francisco spa 4. None of that has changed since we reported the scanner's specs on October 5; what has moved is the courtroom 3. Midjourney has no outside investors; its founder, David Holz, has said subscribers pay the service's costs plus a margin 3.
Those subscribers' outputs are what Disney, Universal and Warner Bros. are suing over. The studios allege $300 million of revenue last year, no court has ruled on the fair-use defense, and a hearing on Midjourney's bid to throw out the claim that it helped users infringe is set for November 23, 2026 3. Damages or an injunction would land on the same subscription revenue that funds the scanner, so the chain from Butterfly's chip to a consumer now crosses a courtroom.
The insider sales were scheduled in August, not timed to the talk
Director Jonathan Rothberg filed notice on November 13, 2026, to sell $2.23 million of stock 5. Chief financial officer John Doherty sold $350,000 of shares two days earlier 6. Investing.com reported DeVivo's own sale at about $635,000 7. The filings on record ran under trading plans adopted in mid-August, weeks before the UBS talk, so they read as scheduled diversification rather than doubt 56. Three days after Rothberg's notice, Hood River Capital, an investment manager holding 4.97 percent of Butterfly's shares, filed a routine passive-ownership update 8.
Adoption, not the chip, is what DeVivo says limits Butterfly
DeVivo's own account puts the limit in the training of the person holding the probe: he named ultrasound's learning curve as the obstacle to wider adoption 1. About 33 companies are building AI tools inside Butterfly's ecosystem that help less-experienced users position probes and acquire images, the step that turns the chip into a clinician's tool 1. Butterfly's community-care program does the same work on the clinical side, training nurses and collecting payment per patient and per scan, with first revenue due this month 12.

One Embedded partner product is on the market, unnamed in the release 2. Until partners beyond Midjourney ship from balance sheets that can pay, the dwarf claim rests on that product, one scanner, one spa and one defendant.
Price the stock on chips shipped by partners that can pay, and treat the UBS quote as a promise until then.
Get Chips by email, free
How AI demand is reshaping chipmakers, memory and the fabs behind them. In our daily email, every weekday.






Reader comments
0 comments